Figure 2.

The modulation of AKT expression does not significantly affect RBL1/p107 levels. (A). A549 cells were treated with 12.5 µM AKTi VIII, 20 µM LY294002 or 1 µM Wortmannin for 1 h (left panel) or 16 h (right panel). RBL1/p107 levels were analyzed by immunoblot. (B). A549 and MSTO-211H cells were transfected with siRNA targeting AKT1 or non-targeting control siRNA and the levels of RBL1/p107 assessed by immunoblot. (C). RBL1/p107 levels as determined in A549 and MSTO-211H cells expressing myristoylated AKT1, AKT2, the combination of myristoylated AKT1 and AKT2 or an empty plasmid. AKT1 and AKT2 were detected using an anti-pan AKT antibody recognizing both AKT1 and AKT2. Quantification was performed by densitometric analysis using the ImageJ program and expressed as % of control. All experiments were performed three times.